Recent advances in extracellular vesicles for therapeutic cargo delivery.

Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. · 2024

Read Recent advances in extracellular vesicles for therapeutic cargo delivery. by Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11059217.txt.

Introduction

Kim and colleagues review natural cell sacs as delivery vehicles for therapy in this 2024 paper. Exosomes are nano-sized sacs cells secrete, and they carry proteins, fats, and nucleic acids between cells. They mix well with body tissue, load varied cargo, and reach deep into tissue. Those traits make them attractive as drug carriers.

The review covers their use in chemotherapy, gene therapy, and heat-based cancer therapy. Because sacs from a patient's own cells are recognised as self, they open a path to personalised treatment. Three hurdles are named plainly: weak cargo loading, fragile structure, and unclear origins of mixed sac batches. The authors call for large-scale production with tight quality control and for more animal and human trials. They still rate sacs as efficient, stable, and safe carriers in prospect.

Catalog record

CREATORKim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D.
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE72 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11059217

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Recent advances in extracellular vesicles for therapeutic cargo delivery By Hyo In Kim, Jinbong Park, Yin Zhu, Xiaoyun Wang, Yohan Han, Duo Zhang Published in: Experimental & Molecular Medicine DOI: 10.1038/s12276-024-01201-6 ABSTRACT Abstract Exosomes, which are nanosized vesicles secreted by cells, are attracting increasing interest in the field of biomedical research due to their unique properties, including biocompatibility, cargo loading capacity, and deep tissue penetration. They serve as natural signaling agents in intercellular communication, and their inherent ability to carry proteins, lipids, and nucleic acids endows them with remarkable therapeutic potential. Thus, exosomes can be exploited for diverse therapeutic applications, including chemotherapy, gene therapy, and photothermal therapy. Moreover, their capacity for homotypic targeting and self-recognition provides opportunities for personalized medicine. Despite their advantages as novel therapeutic agents, there are several challenges in optimizing cargo loading efficiency and structural stability and in defining exosome origins. Future research should include the development of large-scale, quality-controllable production methods, the refinement of drug loading strategies, and extensive in vivo studies and clinical trials. Despite the unresolved difficulties, the use of exosomes as efficient, stable, and safe therapeutic delivery systems is an interesting area in biomedical research. Therefore, this review describes exosomes and summarizes cutting-edge studies published in high-impact journals that have introduced novel or enhanced therapeutic effects using exosomes as a drug delivery system in the past 2 years. We provide an informative overview of the current state of exosome research, highlighting the unique properties and therapeutic applications of exosomes. We also emphasize challenges and future directions, underscoring the importance of addressing key issues in the field. With this review, we encourage researchers to further develop exosome-based drugs for clinical application, as such drugs may be among the most promising next-generation therapeutics. Subject terms: Nanoparticles, Drug delivery INTRODUCTION The use of many traditional drugs is often limited by their poor pharmacokinetics, low bioavailability, and high toxicity. Significant advances in overcoming these challenges and increasing the therapeutic efficacy of drugs have been made in the burgeoning fields of nanotechnology and nanomedicine. Nanomedicines represent a transformative and pervasive field of science in the 21st century, and nanomedicine is a specialized field that utilizes the knowledge and tools of nanotechnology for disease prevention and treatment. Nanomedicines typically include nanoparticles (NPs) that are 1 to 500 nanometers in size1. These tiny particles can be designed to deliver drugs to specific cells, facilitate imaging and diagnostic techniques, or even repair body structures at the cellular level. In addition, nanomedicines can be functionalized with drugs and targeted to specific sites. They offer advantages including high stability, tunable surface properties, and the possibility of combining therapeutic and diagnostic functionalities. For these reasons, nanomedicine is attracting significant research interest2. NPs have attracted significant attention in the field of drug delivery due to their unique properties and ability to overcome various challenges associated with conventional drug delivery systems. NP-based DDSs (nanoparticle-based drug delivery systems) can be used to effectively transport therapeutic agents for the targeted treatment of diseases affecting various organ systems3. These DDSs include both organic and inorganic nanoparticles. Treatment agents can be encapsulated within organic nanoparticles, such as polymeric NPs and liposomes, to maximize their therapeutic effects. Surface modification with ligands can enable targeted drug delivery to specific cells or tissues. Like organic NPs, inorganic nanoparticles composed of materials such as gold, silver, iron oxide, and silica have also been utilized to load drugs and facilitate drug delivery for the treatment of diverse diseases. The use of NPs in DDSs can offer benefits such as increased drug solubility, prolonged release, targeted delivery, reduced toxicity, and heightened therapeutic efficacy4. Although nanoparticles have great potential as drug carriers, adverse immunological responses to nanomedicines, including anaphylaxis, cytokine release syndrome, the neutralization of biological activity, cross-reactivity with endogenous protein counterparts, and delayed immune reactions, have led to termination of the production of various biologicals. Therefore, it is important to perform rigorous preclinical and clinical studies to examine factors including nanoparticle stability, biocompatibility, clearance mechanisms, and potential toxicity in order to ensure their safety and efficacy prior to their use in therapeutic applications5,6. Owing to the occurrence of adverse responses, many scientists have recently focused on exosomes, which are bioproducts generated from various cell lines and thus detected in various body fluids, including blood, urine, bronchoalveolar lavage fluid (BALF), and cerebrospinal fluid (CSF), as new potential drug carriers. Since they are naturally derived, exosomes typically exhibit lower toxicity and greater biocompatibility than synthetic NPs such as liposomes7,8. In addition, exosomes have a unique composition. They consist of a lipid bilayer membrane in which various membrane proteins, such as tetraspanins, glycoproteins, and signaling receptors, are embedded. This structure can naturally encapsulate various genetic substances, including DNAs, RNAs, and proteins. Accordingly, exosomes vary depending on their source and are affected by pathological conditions, which makes them candidate biomarkers for biopsy-based diagnostics9. In addition to their natural properties, exosome surface can be modified to expand the applications of exosomes in nanobiotechnology, particularly in drug delivery systems. The therapeutic application of exosomes depends on the cargoes they transport to target cells as well as on their own characteristics. Exogenous molecules with beneficial effects can be loaded into exosomes using various methods, such as electroporation, sonication, incubation, and/or transfection10. Despite the current technical challenges related to exosome preparation and the efficiency of cargo loading, exosomes have promising therapeutic potential as a new type of drug delivery system. In this review article, we focused specifically on exosomes, which are the most extensively studied type of small extracellular vesicles11. We summarize basic information on exosomes, also known as small extracellular vesicles (sEVs); introduce cargo-loaded exosomes that are currently undergoing testing; and describe the therapeutic effects and advantages in exosome-based drug delivery. Finally, we discuss the therapeutic potential and future directions of this attractive field. CHARACTERISTICS OF EXOSOMES Classification and biogenesis of exosomes Extracellular vesicles (EVs) are highly heterogeneous membrane-bound carriers of various cargoes, including proteins, lipids, and nucleic acids. They are secreted by various cell types under both normal and pathological conditions, participate in intercellular communication, and influence various physiological and pathological processes. EVs are commonly classified as exosomes, microvesicles, or apoptotic bodies according to the mechanism of production12. The three types of EVs differ in their size, origin, and mechanism of formation, but they all serve as means of communication between cells. In addition, they carry various cargoes that reflect their cells of origin and can be delivered to other cells, influencing their function; thus, EVs are recognized as important biomarkers for diagnosis and therapy in many physiological and pathological conditions13,14. Exosomes are the smallest type of EV and are typically 30–150 nanometers in diameter. They originate from the endosomal system within cells. Exosomes contain a variety of molecular constituents, including proteins and RNA, from their cells of origin. Exosome can be taken up by neighboring or distant cells and influence their function. Microvesicles, also known as ectosomes, shedding vesicles, or microparticles, are larger than exosomes and have a diameter of ~100–1000 nanometers. They are formed by direct outward budding and fission of the plasma membrane. Like exosomes, microvesicles contain a variety of molecules from their cells of origin and can influence other cells by fusing with their membranes or by being

Read the complete text